市场调查报告书
商品编码
1533044
欧洲填充成品製造市场预测至 2030 年 - 区域分析 - 按产品、方式和最终用户Europe Fill Finish Manufacturing Market Forecast to 2030 - Regional Analysis - by Product, Modality, and End User |
2022年欧洲填充饰面製造市场价值为24.7326亿美元,预计2030年将达到47.725亿美元;预计2022年至2030年复合年增长率为8.6%。
生物製品需求的增加推动欧洲填补成品製造市场
生物製剂占最畅销药物的大部分,也是成长最快的製药业领域之一。自大约 30 年前推出重组蛋白疗法以来,整个生物製剂市场的年增长率超过 12%。此外,目前有超过 5,000 种生物製药候选产品正在开发中。儘管生物製药提供了可观的利润率,但高开发成本和复杂的生产方案是这些药理学干预措施的发起者的主要关注点。因此,一些新创公司和製药巨头已开始将其业务运营的不同流程外包给合约服务提供者。此外,将工作外包给合约製造组织(CMO)和合约开发与製造组织(CDMO)可以减少资本投资的需求,提供更大的生产能力,缩短产品上市时间,并降低与产品相关的风险。商业化。
填充完成是生产过程的最后一步,也是药品生产中最关键的阶段之一。生物製剂需要特殊的程序和设备来进行填充操作,以确保产品的完整性和安全性。因此,对生物製品需求的成长导致对灵活的无菌填充技术的同等需求。製药商与合约服务提供者合作,利用他们在最新灌装技术方面的经验和专业知识。目前约有 180 家公司为各种生物製品提供灌装製造服务。这些合约製造公司的 350 多家灌装工厂遍布各个地区。
欧洲填充饰面製造市场概览
德国的市场参与者正在采用有机和无机成长策略来扩大和成长市场。例如,2020 年 7 月,总部位于德国拉芬斯堡的合约开发和製造组织 (CDMO) Vetter 宣布,正在投资额外的填充/加工产能,购买奥地利的临床製造基地。
同样,齐格飞集团与德国免疫治疗公司 Biopharmaceutical New Technologies 签署了合作和供应协议,大规模灌装和包装商业数量的创新性 COVID-19 候选疫苗 BNT162b2。成功获得批准后,BioNTech与美国製药公司辉瑞公司合作开发的疫苗将从2021年中期起由齐格飞在其哈默尔恩工厂进行灌装。此外,位于德国的领先生物製药合约开发和製造组织 (CDMO) Rentschler Biotechnologie GmbH 与无菌灌装和完成服务的独立专家 Rentschler Fill Solutions GmbH 宣布建立战略合作伙伴关係,以提供新的最先进的先进的填充和加工设施以及生物製药产品的一站式解决方案,以满足Rentschler Biotechnologie 客户的要求。
欧洲填充成品製造市场收入及 2030 年预测(百万美元)
欧洲填充饰面製造市场细分
欧洲填充饰面製造市场根据产品、模式、最终用户和国家进行细分。根据产品,欧洲灌装製造市场分为消耗品和仪器。到2022年,消耗品细分市场将占据更大的市场份额。
依模式划分,欧洲填充成品製造市场分为重组蛋白、单株抗体、疫苗、细胞疗法及生物疗法、基因疗法等。 2022 年,疫苗领域占据最大的市场。
就最终用户而言,欧洲填充剂製造市场分为合约製造组织、生物製药公司等。 2022 年,合约製造组织细分市场占据最大的市场份额。
根据国家/地区,欧洲填充饰面製造市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2022 年,德国在欧洲填充饰面製造市场份额中占据主导地位。
Becton Dickinson and Co、Gerresheimer AG、Groninger and Co GmbH、IMA Industria Macchine Automatiche SpA、Maquinaria Industrial Dara SL、Nipro Medical Europe NV、NNE AS、Optima Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SGD SA、Stevanato Technology SpA、Sma Packaging Group Gmbh、Schott AG、SG 、和West Pharmaceutical Services Inc 是欧洲填充剂製造市场上的一些领先企业。
The Europe fill finish manufacturing market was valued at US$ 2,473.26 million in 2022 and is expected to reach US$ 4,772.50 million by 2030; it is estimated to grow at a CAGR of 8.6% from 2022 to 2030.
Elevating Demand for Biologics Drives Europe Fill Finish Manufacturing Market
Biologics constitute a majority of the top-selling drugs, and they represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies ~30 years ago, the overall biologics market has grown at an annual rate of more than 12%. Further, over 5,000 biopharmaceutical product candidates are currently under development. Although biopharmaceuticals offer significant profit margins, high development costs and complex production protocols are the key concerns of the sponsors of these pharmacological interventions. As a result, several start-ups and pharmaceutical giants have begun outsourcing different processes of their business operations to contract service providers. Moreover, outsourcing jobs to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) reduces the requirement of capital investments, provides access to larger production capacities, decreases the time-to-market of products, and lowers risks associated with the commercialization of products.
Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Fill finish manufacturing services are currently provided by approximately 180 companies for a variety of biologics. They are located in over 350 fill finish factories for these contract manufacturing companies across various geographic regions.
Europe Fill Finish Manufacturing Market Overview
The market players in Germany are adopting organic and inorganic growth strategies for market expansion and growth. For instance, in July 2020, Vetter, the contract development and manufacturing organization (CDMO), headquarters in Ravensburg, Germany, announced that it is investing in additional fill/finish capacity with the purchase of a clinical manufacturing site in Austria.
Similarly, The Siegfried Group signed a cooperation and supply agreement with Biopharmaceutical New Technologies, a German immunotherapy company, for the large-scale filling and packaging of commercial quantities of BNT162b2, an innovative COVID-19 vaccine candidate. Following successful approval, the vaccine developed by BioNTech in cooperation with Pfizer, an American pharmaceutical company, will be filled by Siegfried at its Hameln site from mid-2021 onwards. Also, Rentschler Biotechnologie GmbH, leading contract development and manufacturing organization (CDMO) for biopharmaceuticals located in Germany, and Rentschler Fill Solutions GmbH, an independent specialist for aseptic fill and finish services, announced a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the requirements of Rentschler Biotechnologie's clients.
Europe Fill Finish Manufacturing Market Revenue and Forecast to 2030 (US$ Million)
Europe Fill Finish Manufacturing Market Segmentation
The Europe fill finish manufacturing market is segmented based on product, modality, end user, and country. Based on product, the Europe fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held a larger market share in 2022. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.
By modality, the Europe fill finish manufacturing market is segmented into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held the largest market share in 2022.
In terms of end user, the Europe fill finish manufacturing market is categorized into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held the largest market share in 2022.
Based on country, the Europe fill finish manufacturing market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe fill finish manufacturing market share in 2022.
Becton Dickinson and Co, Gerresheimer AG, Groninger and Co GmbH, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Europe NV, NNE AS, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc are some of the leading players operating in the Europe fill finish manufacturing market.